Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.04
<C$0.01(5.56%)
At close: 4:00 PM EST
C$0.04
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
C$10.63M
Enterprise ValueC$34.34M
Total Cash (Recent Filing)C$289.24K
Total Debt (Recent Filing)C$18.65M
Price to Earnings (P/E)―
Beta-3.21
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding211,283,630
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low-cost Production HubOperating in Colombia provides structural cost and agronomic advantages for cultivation and extraction, enabling competitive unit economics for pharmaceutical and wellness customers. This geographic footprint supports long-term margin recovery potential once scale and regulatory approvals align.
Positive Gross MarginsA positive gross margin indicates the core product economics can be viable; if selling, scale, and overhead are controlled, revenue growth could translate to profitability. This suggests product-level competitiveness and room to improve operating margins over time.
Improving Cash Burn TrendOperating and free cash flow remain negative but have materially improved versus earlier years, signaling progress in cost control or operational efficiencies. Continued improvement would enhance liquidity and reduce reliance on external financing over the medium term.
Bears Say
Declining RevenueSustained revenue decline and volatile sales hinder the firm's ability to absorb fixed costs and leverage its production base. Without stable, growing top-line demand, margins and cash generation may not improve sufficiently to reach breakeven, prolonging capital needs.
Stressed Balance SheetNegative equity and high debt relative to assets indicate heavy leverage and solvency risk. This reduces financial flexibility, raises refinancing risk, and can force dilutive or costly capital raises, constraining long-term strategic investments and operational recovery plans.
Continued Negative Cash FlowOngoing negative operating and free cash flow mean the company still consumes cash and cannot self-fund growth or debt service. If negative cash flow persists, management will need external financing, which may be scarce or expensive given the weak balance sheet.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$10.63M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is in 22 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 211,283,630 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated medicinal products. Additionally, the company diversifies its offerings by providing telemedicine software. Its clientele spans a range of entities, such as health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies, across both Canada and Colombia. PharmaCielo also holds a strategic partnership with AssuredTrans Inc., and its corporate headquarters are situated in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―